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An automatic reaction control chemical ionization technique in an ion trap detector (ITD) 
was used to quantitate the levels of the cholinergic drug, arecoline, in plasma of treated 
patients with Alzheimer’s disease. The chemical ionization reaction was carried out with 
acetonitrile. The protonated molecules of arecoline (m/z 156) and the internal standard, 
homoarecoline (m/z 170), were monitored. Human plasma samples were extracted with a 
readily evaporable solvent mixture, the residues reconstituted and injecfed along with a 
tertiary amine-carrier into a capillary gas chromatograph interfaced with the ITD. Standard 
curves for plasma-extracted arecoline between ZO-ng/mL and 156-pg/mL levels were linear 
(T z 0.9980). Satisfactory precision (relative standard deviation < 20%) and accuracy (rela- 
tive error < 15%) at the limit of quantitation, 156 pg/mL arecoline, were achieved. Optimal 
conditions for handling of blood samples obtained by venipuncture were determined. The 
assay was successfully applied for the therapeutic monitoring of Alzheimer patients treated 
intravenously with arecoline. (J Am SW Mass Spectrum 1991, 2, 168-173) 
N europathological studies of Alzheimer’s dis- ease (AD) brains indicate a profound degener- ation of cholinergic neurons in the basal fore- 
brain [1, 21 and ventral striatum [3]. The activity of the 
acetylcholine synthesizing enzyme, choline acetyl- 
transferase, is greatly diminished in the diseased 
brain, and the reduction is correlated with severity of 
dementia [4, 51 and the number of senile plaques [6]. 
However, the postsynaptic elements of the choliner- 
gic synapses remain functionally intact; loss of cholin- 
ergic receptors in AD is similar to that of age-matched 
controls [ 71. 
The preservation of central choline@ receptors in 
AD, together with the discovery of a link between the 
cholinergic system and memory function [8], has led 
to therapeutic trials of choline@ agonists to improve 
the cognitive function of AD patients., Arecoline (l), 
the principal alkaloid of Areca cafe&u, is a muscarinic 
cholinergic agonist that readily crosses the 
blood-brain barrier. Although the alkaloid has been 
reported to enhance memory in normal healthy sub- 
jects [9], its therapeutic value in AD remains uncer- 
tain [lo] due potentially to a failure in previous stud- 
ies to achieve and maintain a pharmacologically ade- 
quate brain concentration. 
Comprehensive evaluation in our laboratory of 
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cholinergic supplementation therapy in AD required 
pharmacokinetic analyses of arecoline in human 
plasma and cerebrospinal fluid. Hence, a highly sensi- 
tive and reliable assay procedure was necessary to 
monitor low- and variable-dose regimens of this 
cholinergic drug. The only reported procedure for 
plasma quantitation of arecoline is a combined capil- 
lary gas chromatography (GC) and ammonia chemical 
ionization (CI) mass spectrometry with a detection 
limit from plasma of 1 ng/mL [ll j. The present assay 
utilizes a U technique in an ion trap detector (ITD) 
and homoarecoline (2) [12] as an internal standard. 
While offering a significantly improved sensitivity, the 
technique described here is devoid of chromatogra- 
phy problems of the reported procedure. Also, this 
ion trap methodology could readily be transformed to 
a high-throughput assay suitable for routine monitor- 
ing 
COOR 
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Experimental 
Materials. High-performance liquid chromatographic 
(HPLC)-grade solvents were used: diethyl ether, n- 
hexane, and ethyl acetate were obtained from Fluka 
Chemical Corporation (Ronkonkoma, NY), and 1z- 
pentane and acetonitrile from Burdick & Jackson 
(Muskegon, MI). Reagents, N-ethyldiisopropylamine 
and 1,3-diphenyl-1,1,3,3-tetramethyldisilazane, were 
purchased from Fluka Chemical Corporation. Arecol- 
ine.HBr was purchased from Sigma Chemical Com- 
pany (St. Louis, MO). The free base was obtained by 
basifying with Na,CO,, extracting with diethyl ether, 
and then distilling in vacua. Homoarecoline was pre- 
pared in our laboratory by esterifying arecaidine.HCl 
(Sigma) with ethanol. The free base was isolated, 
purified by microdistillation, and treated with HBr to 
yield homoarecoline.HBr. This salt was recrystallized 
from n-propanol, mp 125-127’C (ref 12, 105°C). The 
structure and purity (> 99%) of homoarecoline were 
ascertained by lH nuclear magnetic resonance and 
GC /MS analyses. 
Buffer solution, pH 9, was prepared by adding 
ammonium hydroxide to 2 M ammonium chloride, 
and was stored at 4°C. Pyrex disposable culture tubes 
(10 mL; PGC Scientifics, Gaithersburg, MD) with 
Teflon-lined caps (PGC Scientifics) were used for 
plasma extractions. Disposable tapered centrifuge 
tubes (5 mL; PGC Scientifrcs) were used to collect and 
evaporate the organic extracts. The sample handling 
tubes were silanized with dimethyldichlorosilane in 
n-hexane, rinsed with methanol, acetonitrile, and air 
dried. Multitube vortexing was carried out in a Tek- 
mar (Cincinnati, OH) Vibrax VXR2 shaker. A Sorvall 
RT 60008 Refrigerated Centrifuge (Du Pont, Wilming- 
ton, DE) was used for separation of the layers after 
plasma extraction, Evaporation was carried out in a 
Pierce (Rockford, IL) Reacti-ThermTM III evaporator. 
The delivery needles of the evaporator were soaked in 
5% acetic acid, washed, and dried after each usage. 
Nitrogen gas was used for evaporation and was puri- 
fied by an In-Line Gas Purifier (Alltech Associates, 
Inc., Deerfield, IL). Blank human plasma samples 
were obtained from the blood bank at the National 
Institutes of Health (Bethesda, MD). 
Gas chromatograph /mass spectrometer (GC/M.S) system. 
A Finnigan (San Jose, CA) Mat 700 Ion Trap Detector 
(ITD”), equipped with Revision 4.0 Automatic Reac- 
tion Control Chemical Ionization (ARC-CI) software, 
was coupled to a Perkin-Elmer (Norwalk, CT) Sigma 
2000 gas chromatograph through a capillary column, 
without a flow restrictor. The GC setup featured a 
split/splitless inlet system with a narrow-bore glass 
Insert, a septum needle guide, teflon-lined septum 
(Alltech), and a J&W (Bodman Chemicals, Aston, 
PA) DB-5 fused-silica capillary column of 30-m x 0.25- 
mm dimensions and 0.2-pm film thickness. Helium 
was used as a carrier gas. It was purified by passing 
through gas purifiers and oxy-traps (Alltech). A linear 
velocity of 30 cm/s at 150°C for helium was main- 
tained through the capillary column. A split vent flow 
of 44 mL/min and septum purge flow of 4 mL/min 
were allowed at the inlet system. The transfer line 
and manifold temperatures of the ITD were main- 
tained at 200 and 22O”C, respectively. The injector 
temperature of the GC was held at 170°C. Samples 
were injected at an oven temperature of 5O’C, and 
after a 30-s delay, the temperature was ramped to 
150°C at 2O”C/min and thereafter at 4”C/min to 16O’C 
and maintained temperature for 1 min. The tempera- 
ture program was terminated after heating the col- 
umn at 180°C for 0.5 min. Samples were injected into 
the GC in the splitless mode for 45 s. Prior to analysis 
of samples, 1,3-diphenyl-1,1,3,3-tetramethyldisilazane 
(0.5 pL) was injected into the GC at 2OO’C in the split 
mode of operation. After one hour at this tempera- 
ture, the GC was conditioned at 1OO’C overnight. The 
septum and glass liner were replaced after approxi- 
mately 50 injections. The liners were reused after 
cleaning with methanol and 30% boiling HNO,, rins- 
ing with distilled water, and drying. 
Chemical ionization was carried out with acetoni- 
bile reagent gas. For this, HPLC-grade acetonihile 
(Burdick & Jackson) was placed in a vial and its vapor 
was introduced into the ITD source via a metering 
valve at ambient temperature. Since the partial pres- 
sure of the reagent gas could not be monitored on the 
l’l’D, the metering valve was adjusted to give 
3000-4000 counts for the protonated acetonitrile, m/z 
42. This was done in the instrumental setup mode of 
the software at 200 V below a 105-gain voltage setup 
of the electron multiplier. Parameters for the reaction 
were optimized as follows: peak height of the reagent 
ion was plotted against a range of ionization radio 
frequency (rf) levels to determine an optimum value 
(135.5 mV, 8.6 u in the software) for its efficient 
trapping, and, analogously, the reaction rf level (283.5 
mV, 18 u in the software) for trapping of the product 
ion was chosen by measuring the ion current for the 
protonated arecoline (on-column 1.5 ng, triplicate) at 
different rf levels. Maximum ionization time and reac- 
tion time used were 700 ps and 40 ms, respectively. 
Both background mass and low scan limit were set at 
120 u. A filament current of 60 PA and an electron 
multiplier voltage of 50-100 V above the 105-gain 
voltage were utilized for detection. Data were ac- 
quired only over the mass range 155-171 u in the 
normal ITD scan acquisition mode. This allowed the 
averaging of 16 scans every half-second by the data 
system for final output. Reconstructed ion chro- 
matograms were created postrun (m/z 156 and 170 
for arecoline and homoarecoline, respectively). The 
operating sensitivity (parameter “B” of the software) 
of the mass spectrometer was 2700 units. 
Preparation of stock solutions and plasma standards. 
Equivalent amounts of arecoline.HBr or homoarecol- 
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ineHl3r were dissolved in a mixture of acetonitrile 
and ethyl acetate (95 : 5, v/v) to provide stock solu- 
tions containing 1 mg/mL of free base. Stock solu- 
tions were stored at 4°C and changed monthly. A 
working standard solution of arecoline (20 ng/mL) 
was prepared daily. An aliquot of this solution was 
serially diluted to obtain 10 ng, 5 ng, 2.5 ng, 1.25 ng, 
625 pg, 312.5 pg, and 156 pg of arecoline, each in 100 
pL. The stock solution of homoarecoline was diluted 
to provide a concentration of 25 ng in 100 pL. These 
dilutions were carried out in silanized tubes with the 
same solvent mixture used for preparing the stock 
solutions. Blank human plasma samples (1 mL) were 
cooled to 4”C, spiked with 100 PL of each of the 
working standard solutions (20 ng to 156 pg) of arecol- 
ine, and mixed. The resulting standard plasma sam- 
ples used for the generation of the standard curve 
were prepared on each day of analysis. 
Extraction procedure. Standard plasma samples or 
plasma (1 mL each) obtained from patients receiving 
arecoline were spiked with lOO-pL aliquots (25 ng) of 
the internal’ standard, homoarecoline, solution. The 
contents of the tubes were mixed and basified by the 
addition of 100 fiL of ammonia buffer (2 M; pH 9). A 
mixture of pentane and diethyl ether (80 : 20, v/v) was 
cooled to 4°C in a dispenser, and 5 mL delivered to 
each tube. These were vortexed for 5 min and then 
centrifuged at 1000 g for 5 mm at 4°C. The tubes 
were immersed in dry ice until the aqueous layers 
froze, and the top organic layers were poured into 
tapered centrifuge tubes. The organic extracts were 
concentrated by evaporating the solvents under a 
stream of N, gas at 80-mL/min flow. The heating 
blocks of the evaporator were at ambient temperature. 
The residues were reconstituted in 25 pL of n-hexane 
containing 1% N-ethyldiisopropylamine, and 1.5~pL 
aliquots were injected into the GC/MS. 
Recowy study. Plasma recovery of arecoline at a con- 
centration of 10 ng/mL was determined by using 
homoarecoline (free base) as an external standard. Six 
replicate spiked’ plasma samples were extracted, 4-mL 
ahquots of the organic layers were removed, 25 ng of 
homoarecoline was added to each, mixed, and solvent 
evaporated. The amount of arecoline partitioned into 
the organic phase was determined from the caiibra- 
tion curve generated by the use of homoarecoline 
(free base) as an internal standard. The absolute 
amount of arecoline recovered in 5 mL of the organic 
phase was calculated and expressed as a percentage 
of the added amount. 
Stability study. Freshly drawn human whole blood, 
10 mL, was placed in heparinized tubes in a 37°C 
water bath. An aqueous solution of arecoline.HBr was 
added to each tube to a fmal concentration equivalent 
of 10 ng/mL free base. Immediately, duplicate sam- 
ples were incubated at 37”C, room temperature 
(21’(Y), and 4°C. Samples of blood, 2 mL, were re- 
moved from each tube at 0-, lo-, 3O-, and 60-min 
intervals, the plasma separated and frozen to - 8O’C. 
Arecoline levels in these samples were quantitated 
after the addition of the internal standard. In a sepa- 
rate study, human plasma spiked with arecoline, 1.25 
ng/mL, was stored at -8O’C for four months and 
then quantitated. 
Precision and accuracy. Within-day assay precision 
was determined by spiking six replicate plasma sam- 
ples with arecoline at concentrations of 10 ng/mL, 
1.25 ng/mL, and 156 pg/mL. Amounts were quanti- 
tated on the same day with a standard curve. Be- 
tween-day variation was determined at a concentra- 
tion of 1.25 ng/mL. This amount of arecoline con- 
tained in a pooled blank plasma (10 mL), was divided 
into 1-mL portions and stored at -80°C. The frozen 
samples were analyzed for arecoline content on sepa- 
rate days from different calibration curves generated 
over a period of four months. 
Results and Discussion 
Critical to the development of a sensitive and repro- 
ducible assay for arecoline is a judicious choice of the 
sample preparation procedure and instrumentation 
setup, compatible with the sensitive physicochemical 
properties of the molecule. The volatility, hydrolytic 
breakdown, and adsorptive nature of arecoline were 
considered in all stages of the assay. 
Ion trap defection. Ion traps have gained popularity as 
sensitive and reliable mass spectrometers in recent 
years. As they are trapping devices and capable of 
producing a large population of reagent ions at a 
lower reagent gas pressure compared to conventional 
mass spectrometers, ion traps are readily adaptable to 
perform CI reactions. In our work, the ITD was found 
to provide approximately 10 times more sensitivity in 
ARC-C1 mode than in electron ionization [13], when 
other variables are constant. This is true irrespective 
of the nature of the analyte (standard or plasma-ex- 
tracted sample). 
Acefonitrile as reagent gas. The traditional reagent gas, 
methane, causes significant hydride abstraction of 
arecoline. This process is significantly less pro- 
nounced if CI reaction is carried out with acetomtrile. 
The usefulness of acetonitrile as a reagent gas for ITD 
was previously reported [14]. The ion-molecule reac- 
tion of acetonitrile in the ITD source yields approxi- 
mately 90% of the protonated molecule, m/z 42, and 
10% of an adduct ion, m/z 54. The latter ion may be 
due to isomeric [CaH4N]* species [15, 161. When 
deuterated acetonitriie (C’H,CN), alone or mixed 
with equimolar protio analogue, was introduced into 
the source, expected deuterium mass shifts for these 
ionic species were observed. The coefficient of varia- 
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tion for the reagent ion count was less than 4% when 
checked periodically over a period of eight hours. 
This indicates a constant flow of acetonitrile vapor 
into the ITD source, a desirable characteristic of a CI 
gas, particularly for use in quantitative studies. The 
ARC-C1 parameters for this reagent gas also were 
optimized in its present quantitation usage. 
Cqillay GC. Standard or plasma-extracted arecoline 
samples were eluted off the capillary column as single 
sharp peaks with minimum interference from the ma- 
trix components. This required optimization of the 
temperature program as well as injector temperature. 
Also at the chosen temperature (170°C) of the injec- 
tor, most of the high-boiling components of the plasma 
extract were retained in the sleeve of the inlet, and as 
a result the lie of the column was prolonged. After 
removal of an approximately l-cm piece, the capillary 
column was periodically rejuvenated by injecting a 
small amount of silylating agent, 1,3-diphenyl- 
1,1,3,3-tetramethyldisilazane [17]. The column perfor- 
mance was found to remain unaffected even after 
analysis of 1000 samples. 
Choice of internal standard. The selection of internal 
standards (labeled or unlabeled) for ion traps in quan- 
titations has been discussed in earlier works [18, 191. 
In these, the traps were operated in rf-only, rf/dc or 
rf/dc tandem mass spectrometry modes under elec- 
tron ionization. A homologue of arecoline, ho- 
moarecoline, rather than an isotopically labeled ana- 
logue was found suitable in the present ARC-C1 setup 
of ITD. This program linearly adjusts both ionization 
time and reaction time, while detecting a wide range 
of concentrations of an analyte, to prevent space- 
charge effects [20]. In such a setup, detection of a 
relatively high concentration of internal standard and 
low concentration of analyte in the same time do- 
main, as in quantitation with a co-eluting isotopically 
labeled internal standard, may not be achievable. 
When [‘Hslarecoline [21] was used as an internal 
standard for plasma quantitation of arecoline, sub- 
nanogram level of quantitation was not attainable. 
Typically, below 1.25 ng/mL level of analyte detec- 
tions, peaks were poorly defined and accompanied by 
loss of linear response. It appears that for arecoline 
and perhaps other analytes, chemical analogues are 
appropriate internal standards for sensitive quantita- 
tions using lTD in its current scan functions. Con- 
versely, in narrow dynamic ranges ARC-C1 detections 
with labeled internal standards may be achievable. 
Extraction and reconstitdion. A suitable solvent sys- 
tem and conditions for extraction were determined to 
optimize both quality and yield of the analyte, arecol- 
ine, from human plasma. The effect of pH, ranging 
between 4 and 12, on the partitioning of arecoline 
between aqueous layer and organic phase was stud- 
ied. Maximum arecoline was recovered at pH 9.0; a 
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Figure 1. Acetonitrik CI spectra of (a) arecoline and (b) ho- 
moarecolme; and ion chromatograms for (c) control blank 
plasma, (d) plasma spiked with 154 pg/mL arecoline, (e) esti- 
mated 139 pg/mL arecoline in the plasma of an Alzheimer 
patient 62 min after termination of continuous intravenous infu- 
sion of the drug, and (f) 25 ng/mL internal standard; 1 mL 
plasma was used in each case. 
higher pH reduced recovery, probably as a conse- 
quence of hydrolysis. Therefore, plasma samples were 
extracted at pH 9.0 to obtain optimal recovery of the 
analyte. The use of a relatively high-boiling-point 
solvent, such as ethyl acetate, proved unsuitable for 
extraction, as sign&ant amount of arecoline is lost by 
evaporation (data not shown). A volatile solvent, such 
as diethyl ether, obviated this problem, but drying of 
the hydrated solvent posed another procedural dif- 
ficulty. Subsequently, a mixture of n-pentane and 
diethyl ether (80 : 20 v/v) was found to provide a 
clean extraction of arecoline from the plasma. A five- 
fold excess of this solvent mixture was used for maxi- 
mum recovery of the analyte in a single extraction. 
After solvent evaporation, the residue was reconsti- 
tuted in n-hexane containing 1% N-ethyldiisopro- 
pylamine. This nonnucleophilic amine, while main- 
taining a basic milieu in the inlet and column, served 
as a good carrier for both the amines, arecoline and 
homoarecoline (internal standard), which were in- 
jected in nanogram-to-picogram amounts. Co-injec- 
tion of N-ethyldiisopropylamine greatly reduced peak 
tailing and improved the linearity of detection. 
Acquisition. The acetonitrile CI mass spectra of areco- 
line and homoarecoline are shown in Figure la and b, 
respectively. A segment of ions, inclusive of m/z 156 
and 170 for protonated arecoline and homoarecoline, 
respectively, was monitored in the plasma quantita- 
lions. Peaks for the individual ion current of arecoline 
and the internal standard were then constructed. Fig- 
ure lc and d show the ion chromatograms for control 
blank plasma and for plasma spiked with arecolme 
(156 pg/mL), respectively. An ion chromatogram for 
the Internal standard (25 ng/mL) is shown in Figure 
If. Peaks for arecoline and homoarecoline appeared 
with retention times of 7 min 8 s and 7 min 56 s, 
respectively. Occasionally, weak peaks, possibly of 
electron multiplier noise or of chromatographic back- 
ground, occurred in the vicinity of the arecoline peak 
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Figure 2. Representative standard curve generated by plotting 
logarithmic concentrations of arecoline (ng/mL plasma) versus 
logarithmic rak area ratios, arecoline to the internal standard; 
y = 0.0307X .==, 7 = 0.9980. 
when quantitating low concentrations, 156 pg/mL 
(Figure Id). However, these sporadic peaks made up 
less than 10% of the signal peak and their effect on 
the accuracy of the assay is insignihcant. 
Sensitivity and lineatity. The lower limit of detection 
of a standard amount of arecoline by GC/MS was not 
determined, although for spiked plasma it was 78 
pg/mL, at a signal-to-noise ratio of 4. The lower limit 
of quantitation was 156 pg/mL. In all analyses only 
6% of the fmal sample was injected to GC/MS, result- 
ing in 9.4 pg to 1.2 ng of analyte on-column with 1.5 
ng internal standard. Standard curves were con- 
structed by pIotting logarithmic ratios of the peak 
areas of arecoline (m/z 156) to the internal standard 
(m/z 170) against the logarithmic plasma concentra- 
tions of arecoline. Regression lines, generated by us- 
ing logarithmic data, provided accurate estimates of 
unknown amounts of arecoline over a hundredfold 
concentration range. A typical standard curve illus- 
trating the linearity (T = 0.9980) of detection for an 
arecoline concentration range between 20 ng/mL and 
156 pg/mL is shown in Figure 2. 
Rewvey and reproducibility. Using homoarecoline free 
base as an external standard, quantitation of arecoline 
z 10 - 
3 
CT 8-----__ 4Oc 
21°C 
37 “c 
IO 20 30 40 50 60 
Time, min 
Figure 3. Effect of incubation temperature on the stability of 
arecoline (10 ng/mL) in human whole blood. 
in the organic phase following extraction from plasma 
allowed the determination of percentage recovery. At 
a concentration of 10 ng/mL, the recovery of arecolme 
was 89 + 6% (mean ks.d., n = 6). Reproducibility of 
the assay was evaluated by replicate analyses of the 
spiked plasma samples at the limit of quantitation and 
also at higher concentrations along the standard curve. 
The precision (relative standard deviation of replicate 
analyses) and accuracy (relative error of the measure- 
ments) of the assay are summarized in Table 1. These 
are satisfactory for both within-day and between-day 
variations, and therefore the assay procedure is appli- 
cable for routine therapeutic monitoring of arecoline. 
Stability. During therapeutic monitoring, it is as- 
sumed that the drug remains undegraded between 
the time blood is withdrawn from treated subjects and 
the time plasma is separated and frozen for storage. 
Arecoline is rapidly hydrolyzed to its carboxylic acid, 
arecaidine, in liver homogenate preparations [22]. This 
labile ester probably is hydrolyzed in blood by acetyl- 
choline esterase and nonspecific esterases. To mini- 
mize the loss of analyte during handling of blood and 
plasma prior to analysis, the effect of temperature on 
the stability of arecolme in the blood was studied. 
Arecoline was incubated in fresh human blood at 
37”C, 21°C (room temperature), and 4-C, and ana- 
lyzed during 60 min. Figure 3 shows that arecoline is 
minimally metabolized in blood up to 60 min if main- 
Table 1. Precision and accuracy data 
Concentration found Number of Relative standard Relative 
Precision type Concentration added (mean f s.d.1 replicates deviation 1%)” wror (%)b 
Within-day 10 ng/mL 10.72 f 0.43 ng/mL 6 4.0 +7.2 
1.25 ng/mL 1.22 + 0.13 ng/mL 6 10.8 -2.4 
156 pg /mL 175 * 27 pg/mL 6 15.5 +12.2 
Between-day 1.25 ng/mL 1.36 f 0.07 ng /mL 5 5.1 +8.8 
‘(s.d./% 100 
bIIConcentration found - concentration addedljconcentration added] 100 
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Figure 4. Plasma concentration time course of arecoline follow- 
ing a 2%min continuous intravenous infusion of amcoline, 5 
mg, to a patient with Alzheimer’s disease. 
tained at 4-C. Therefore, blood samples from treated 
patients were collected in chilled tubes and immersed 
immediately in an ice bath. Plasma was immediately 
separated at 4’C and frozen. The stability of arecoline 
was checked in frozen plasma samples. No degrada- 
tion of arecoline, 1.25 ng/mL, occurred in plasma 
during four months of storage at - 80-C. 
Therapeutic monitoring. The applicability of this ana- 
lytical technique was tested in human studies. In one 
clinical evaluation, AD patients received a 5-mg dose 
of arecoline as a continuous intravenous infusion over 
a period of 28 min. Blood samples were collected at 
timed intervals during infusion and up to 60 min 
postinfusion to determine the disposition characteris- 
tics of the drug. A time-dependent plasma concentra- 
tion profile of arecoline in one subject is shown in 
Figure 4. The assay procedure proved sufficiently sen- 
sitive and specific to precisely measure concentrations 
at the terminal portion of the curve without interfer- 
ence from metabolites or endogenous compounds. 
The ion chromatogram for the last estimated arecoline 
concentration, 139 pg/mL, on the time-dependent 
concentration profile is shown in Figure le. 
The pharmacokinetic analysis of arecoline in AD 
patients, including its efficacy in relation to plasma 
levels, will be reported elsewhere. 
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